CapsoVision reported $3.6 million in sales for the third quarter and launched a new AI tool to boost growth.

Nov 12, 2026, 4:37 PM ETResultsRead the original at SEC EDGAR

Neutral

CapsoVision launched its cleared AI reading tool and finished enrollment in its colon study, but sales barely rose, gross margin fell, and losses continued. Share sales added cash, but these mixed changes do not clearly shift the company's outlook.

CV · CapsoVision, Inc.

AI read · Neutral

The AI's read

The AI tool may help doctors review scans faster. Wider use of the capsule and completed colon-study enrollment also create room for growth, but an FDA submission is still planned, not completed. Sales barely rose, and gross profit and gross margin fell. The loss and expenses declined, but the company still lost money. Share offerings brought in cash by issuing shares. With the AI tool's full sales effect expected in 2027, the quarter's gains and setbacks point in different directions.

Get alerts for CV

Follow CapsoVision, Inc. (CV) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CV

Free on the App Store and Google Play, or on the web.